Vanguard reports 0 shares of Repligen (Schedule 13G/A)
The Vanguard Group filed Amendment No. 7 to Schedule 13G/A reporting no beneficial ownership of Repligen Corp common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 7 to Schedule 13G/A reporting no beneficial ownership of Repligen Corp common stock. The filing states 0 shares beneficially owned, representing 0% of the class, and shows zero voting and dispositive power. The amendment notes an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report ownership separately.
The filing lists Vanguard’s principal office at 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Vanguard report for RGEN ownership in this Schedule 13G/A amendment?
Why did The Vanguard Group change its reporting in the RGEN filing?
Who signed the RGEN Schedule 13G/A Amendment No. 7 for Vanguard?
Where is Vanguard’s principal business address listed in the RGEN amendment?
AI-generated analysis. How Rhea-AI works. Not financial advice.